Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Sweden Urges Shareholders to Reject AstraZeneca Takeover

Swedish Finance Minister Anders Borg urged shareholders of AstraZeneca Plc to reject a takeover by Pfizer Inc., saying the deal risks hurting the Nordic nation's economy. Photographer: Andrew Harrer/Bloomberg
Swedish Finance Minister Anders Borg urged shareholders of AstraZeneca Plc to reject a takeover by Pfizer Inc., saying the deal risks hurting the Nordic nation's economy. Photographer: Andrew Harrer/Bloomberg

May 16 (Bloomberg) -- Sweden’s government urged shareholders of AstraZeneca Plc to reject a takeover by Pfizer Inc., saying the deal risks hurting the largest Nordic economy.

“What we’re now seeing is a hostile process where a very important reason for the deal seems to be” to cut Pfizer’s tax burden, Finance Minister Anders Borg said today in Stockholm. “There’s a worry that tax-driven deals can result in that potential profits will be achieved through cost cuts.”

Pfizer is meeting opposition from policy makers in Sweden and the U.K. on concern the U.S. company’s proposed $102 billion takeover will cost research jobs. U.K. lawmakers this week questioned Pfizer executives and Sweden’s government is escalating its opposition in an election year.

Borg this week said he has spoken to the U.K. government about his concerns that the deal is driven by taxes and may result in job cuts. Since Sweden’s Astra AB was bought by Zeneca Plc in 1999, the company has reduced its presence in the country. Its workforce in Sweden now stands at 5,900, about 11 percent of the London-based company’s total and down from 8,419 in 2008 before the shuttering of sites in Lund and Soedertaelje.

No Returns

According to Borg, about 60 percent to 70 percent of similar deals don’t generate “good returns” for shareholders and society. He earlier told reporters that Pfizer’s actions weakens Sweden’s resistance against those members in the European Union who argue countries should introduce regulation to protect themselves against foreign takeovers.

“It’s an activity where we are very big financiers,” Borg said. “We’ve invested a lot of resources, more than most countries, in life science.”

Pfizer, based in New York, made an initial offer in January, citing the company’s promising product pipeline and the ability to change its headquarters to the U.K. to gain a corporate tax cut. AstraZeneca has since rejected a raised offer and Chief Executive Officer Pascal Soriot said on May 14 that a sale of the U.K. drugmaker is “not inevitable.”

Pfizer plans to raise its offer again, people with knowledge of the matter have said.

To contact the reporters on this story: Johan Carlstrom in Stockholm at jcarlstrom@bloomberg.net; Niklas Magnusson in Stockholm at nmagnusson1@bloomberg.net

To contact the editors responsible for this story: Jonas Bergman at jbergman@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.